Access Bio, Inc. (KOSDAQ:950130)
2,570.00
0.00 (0.00%)
Sep 1, 2026, 3:30 PM KST
Access Bio Revenue
Access Bio had revenue of 9.54B KRW in the quarter ending June 30, 2026, with 593.59% growth. This brings the company's revenue in the last twelve months to 23.54B, down -68.31% year-over-year. In the year 2025, Access Bio had annual revenue of 31.26B, down -72.21%.
Revenue (ttm)
23.54B
Revenue Growth
-68.31%
P/S Ratio
3.84
Revenue / Employee
233.05M
Employees
101
Market Cap
90.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.26B | -81.21B | -72.21% |
| Dec 31, 2024 | 112.46B | -236.18B | -67.74% |
| Dec 31, 2023 | 348.64B | -685.22B | -66.28% |
| Dec 31, 2022 | 1.03T | 528.75B | 104.68% |
| Dec 31, 2021 | 505.11B | 383.31B | 314.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Boditech Med | 174.78B |
| DRTECH | 126.23B |
| Dongbang Medical | 125.12B |
| Ray Co., Ltd. | 119.17B |
| Shinhung | 105.89B |
| Bio Plus | 94.42B |
| JETEMA, | 76.58B |
| Humasis | 32.87B |